KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with $0.41 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 315.79% year-over-year to $0.41, compared with a TTM value of $0.01 through Dec 2025, up 100.69%, and an annual FY2025 reading of $1.21, up 183.45% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.41 for Q4 2025 at Teva Pharmaceutical Industries, down from $0.55 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.55 in Q3 2025 and bottomed at -$1.18 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.12, with a median of -$0.04 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 1328.57% in 2022, then surged 315.79% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.14 in 2021, then tumbled by 742.86% to -$1.18 in 2022, then skyrocketed by 134.75% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then soared by 315.79% to $0.41 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TEVA at $0.41 in Q4 2025, $0.55 in Q3 2025, and $0.17 in Q2 2025.